The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis.

ABSTRACT: Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT₁R) levels are associated with poor prognosis in CRC patients. Recently, we have revealed the role of the tumor promoter CysLT₁R in drug resistance and stemness in colon cancer (CC) cells. Here, we show the role of the CysLT₁R/Wnt/β-catenin signaling axis in the regulation of PD-L1 using both in vitro and in vivo preclinical model systems. Interestingly, we found that both endogenous and IFNγ-induced PD-L1 expression in CC cells is mediated through upregulation of Cys

SUBMITTER: Satapathy SR 

PROVIDER: S-EPMC10265834 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature